fda warning letters compounded semaglutide october 2025 September 15, 2025: Telehealth company must stop implying its GLP-1 is FDA-approved, warns – Partnership for Safe Medicines How GLP-1s Broke Healthcare Distribution
Description
95% CI, 0.20 to 0.32) and recurrent (HR, 0.44
These halo effects skew higher for Gen Z and millennial consumers, the research continues
Why so long
They had more muscle mass, less loose skin issues, higher metabolic rates, and better physical function
Challenges and Future Outlook for Pharma Marketers Despite the promise of DTC telehealth, challenges remain
Participants treated with liraglutide (239), semaglutide (240), or tirzepatide (200) in the clinical trials had a percent reduction in fat mass approximately three times greater than the reduction in lean mass, leading to an overall improvement in body composition
